Literature DB >> 21521850

Association of CTNNB1 (beta-catenin) alterations, body mass index, and physical activity with survival in patients with colorectal cancer.

Teppei Morikawa1, Aya Kuchiba, Mai Yamauchi, Jeffrey A Meyerhardt, Kaori Shima, Katsuhiko Nosho, Andrew T Chan, Edward Giovannucci, Charles S Fuchs, Shuji Ogino.   

Abstract

CONTEXT: Alterations of the WNT signaling pathway and cadherin-associated protein β 1 (CTNNB1 or β-catenin) have been implicated in colorectal carcinogenesis and metabolic diseases.
OBJECTIVE: To test the hypothesis that CTNNB1 activation in colorectal cancer modifies prognostic associations of body mass index (BMI) and level of postdiagnosis physical activity. DESIGN, SETTING, AND PATIENTS: Two US prospective cohort studies (Nurses' Health Study and the Health Professionals Follow-up Study) were used to evaluate CTNNB1 localization by immunohistochemistry in 955 patients with stage I, II, III, or IV colon and rectal cancer from 1980 through 2004. A Cox proportional hazards model was used to compute the hazard ratio (HR) for mortality, adjusting for clinical and tumor features, including microsatellite instability, CpG island methylator phenotype, level of long interspersed nucleotide element 1 methylation, mutations in KRAS, BRAF, or PIK3CA, and tumor protein p53. MAIN OUTCOME MEASURES: Colorectal cancer-specific mortality and overall mortality through June 30, 2009.
RESULTS: In obese patients (BMI ≥30), positive status for nuclear CTNNB1 was associated with significantly better colorectal cancer-specific survival (adjusted HR, 0.24 [95% confidence interval {CI}, 0.12-0.49], P <.001 for interaction; 5-year survival: 0.85 for patients with positive nuclear CTNNB1 status vs 0.78 for those with negative status) and overall survival (adjusted HR, 0.56 [95% CI, 0.35-0.90], P = .03 for interaction; 5-year survival: 0.77 for patients with positive nuclear CTNNB1 status vs 0.74 for those with negative status), while CTNNB1 status was not associated with prognosis among nonobese patients (BMI <30). Among patients with negative status for nuclear CTNNB1 and cancer in stages I, II, or III, postdiagnosis physical activity was associated with better colorectal cancer-specific survival (adjusted HR, 0.33 [95% CI, 0.13-0.81], P = .05 for interaction; 5-year survival: 0.97 for ≥18 vs 0.89 for <18 metabolic equivalent task hours/week), while postdiagnosis physical activity was not associated with colorectal cancer-specific survival among patients with positive status for nuclear CTNNB1 (adjusted HR, 1.07 [95% CI, 0.50-2.30]).
CONCLUSIONS: Among obese patients only, activation of CTNNB1 was associated with better colorectal cancer-specific survival and overall survival. Postdiagnosis physical activity was associated with better colorectal cancer-specific survival only among patients with negative status for nuclear CTNNB1. These molecular pathological epidemiology findings suggest that the effects of alterations in the WNT-CTNNB1 pathway on outcome are modified by BMI and physical activity.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21521850      PMCID: PMC3087286          DOI: 10.1001/jama.2011.513

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  58 in total

1.  L1, β-catenin, and E-cadherin expression in patients with colorectal cancer: correlation with clinicopathologic features and its prognostic significance.

Authors:  Qing-Xia Fang; Liang-Zhong Lü; Bo Yang; Zhong-Sheng Zhao; Yue Wu; Xiao-Chun Zheng
Journal:  J Surg Oncol       Date:  2010-10-01       Impact factor: 3.454

2.  Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab.

Authors:  Wendy De Roock; Derek J Jonker; Federica Di Nicolantonio; Andrea Sartore-Bianchi; Dongsheng Tu; Salvatore Siena; Simona Lamba; Sabrina Arena; Milo Frattini; Hubert Piessevaux; Eric Van Cutsem; Chris J O'Callaghan; Shirin Khambata-Ford; John R Zalcberg; John Simes; Christos S Karapetis; Alberto Bardelli; Sabine Tejpar
Journal:  JAMA       Date:  2010-10-27       Impact factor: 56.272

3.  PIK3CA mutation is associated with poor prognosis among patients with curatively resected colon cancer.

Authors:  Shuji Ogino; Katsuhiko Nosho; Gregory J Kirkner; Kaori Shima; Natsumi Irahara; Shoko Kure; Andrew T Chan; Jeffrey A Engelman; Peter Kraft; Lewis C Cantley; Edward L Giovannucci; Charles S Fuchs
Journal:  J Clin Oncol       Date:  2009-02-23       Impact factor: 44.544

4.  Lifestyle factors and microsatellite instability in colorectal cancer: the evolving field of molecular pathological epidemiology.

Authors:  Shuji Ogino; Meir Stampfer
Journal:  J Natl Cancer Inst       Date:  2010-03-05       Impact factor: 13.506

5.  Cytoplasmic beta-catenin accumulation is a good prognostic marker in upper and lower gastrointestinal adenocarcinomas.

Authors:  Michael G A Norwood; Neil Bailey; Manoj Nanji; Richard S Gillies; Anna Nicholson; Sukh Ubhi; Jane J Darnton; Richard S Steyn; Chris Womack; Andrew Hughes; David Hemingway; Rebecca Harrison; Rachel Waters; Janusz A Jankowski
Journal:  Histopathology       Date:  2010-06-21       Impact factor: 5.087

6.  AMP-activated protein kinase (AMPK) cross-talks with canonical Wnt signaling via phosphorylation of beta-catenin at Ser 552.

Authors:  Junxing Zhao; Wanfu Yue; Mei J Zhu; Nair Sreejayan; Min Du
Journal:  Biochem Biophys Res Commun       Date:  2010-03-31       Impact factor: 3.575

7.  Obesity is an independent prognostic variable in colon cancer survivors.

Authors:  Frank A Sinicrope; Nathan R Foster; Daniel J Sargent; Michael J O'Connell; Cathryn Rankin
Journal:  Clin Cancer Res       Date:  2010-03-09       Impact factor: 12.531

8.  Physical activity and male colorectal cancer survival.

Authors:  Jeffrey A Meyerhardt; Edward L Giovannucci; Shuji Ogino; Gregory J Kirkner; Andrew T Chan; Walter Willett; Charles S Fuchs
Journal:  Arch Intern Med       Date:  2009-12-14

9.  Precision of pyrosequencing assay to measure LINE-1 methylation in colon cancer, normal colonic mucosa, and peripheral blood cells.

Authors:  Natsumi Irahara; Katsuhiko Nosho; Yoshifumi Baba; Kaori Shima; Neal I Lindeman; Aditi Hazra; Eva S Schernhammer; David J Hunter; Charles S Fuchs; Shuji Ogino
Journal:  J Mol Diagn       Date:  2010-01-21       Impact factor: 5.568

10.  Aspirin use and survival after diagnosis of colorectal cancer.

Authors:  Andrew T Chan; Shuji Ogino; Charles S Fuchs
Journal:  JAMA       Date:  2009-08-12       Impact factor: 56.272

View more
  110 in total

1.  Dietary glycemic and insulin scores and colorectal cancer survival by tumor molecular biomarkers.

Authors:  NaNa Keum; Chen Yuan; Reiko Nishihara; Emilie Zoltick; Tsuyoshi Hamada; Alejandro Martinez Fernandez; Xuehong Zhang; Akiko Hanyuda; Li Liu; Keisuke Kosumi; Jonathan A Nowak; Iny Jhun; T Rinda Soong; Teppei Morikawa; Fred K Tabung; Zhi Rong Qian; Charles S Fuchs; Jeffrey A Meyerhardt; Andrew T Chan; Kimmie Ng; Shuji Ogino; Edward L Giovannucci; Kana Wu
Journal:  Int J Cancer       Date:  2017-03-28       Impact factor: 7.396

2.  No evidence for interference of h&e staining in DNA testing: usefulness of DNA extraction from H&E-stained archival tissue sections.

Authors:  Teppei Morikawa; Kaori Shima; Aya Kuchiba; Mai Yamauchi; Noriko Tanaka; Yu Imamura; Xiaoyun Liao; Zhi Rong Qian; Mohan Brahmandam; Janina A Longtine; Neal I Lindeman; Charles S Fuchs; Shuji Ogino
Journal:  Am J Clin Pathol       Date:  2012-07       Impact factor: 2.493

3.  Clinical implications of β-catenin protein expression in breast cancer.

Authors:  Ziyi Wang; Hao Zhang; Jianxin Hou; Jianing Niu; Zhenhai Ma; Haidong Zhao; Caigang Liu
Journal:  Int J Clin Exp Pathol       Date:  2015-11-01

4.  Body mass index and risk of colorectal cancer according to fatty acid synthase expression in the nurses' health study.

Authors:  Aya Kuchiba; Teppei Morikawa; Mai Yamauchi; Yu Imamura; Xiaoyun Liao; Andrew T Chan; Jeffrey A Meyerhardt; Edward Giovannucci; Charles S Fuchs; Shuji Ogino
Journal:  J Natl Cancer Inst       Date:  2012-02-06       Impact factor: 13.506

Review 5.  Harnessing cancer immunotherapy during the unexploited immediate perioperative period.

Authors:  Pini Matzner; Elad Sandbank; Elad Neeman; Oded Zmora; Vijaya Gottumukkala; Shamgar Ben-Eliyahu
Journal:  Nat Rev Clin Oncol       Date:  2020-02-17       Impact factor: 66.675

6.  Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival.

Authors:  Xiaoyun Liao; Paul Lochhead; Reiko Nishihara; Teppei Morikawa; Aya Kuchiba; Mai Yamauchi; Yu Imamura; Zhi Rong Qian; Yoshifumi Baba; Kaori Shima; Ruifang Sun; Katsuhiko Nosho; Jeffrey A Meyerhardt; Edward Giovannucci; Charles S Fuchs; Andrew T Chan; Shuji Ogino
Journal:  N Engl J Med       Date:  2012-10-25       Impact factor: 91.245

Review 7.  Role of physical activity and diet after colorectal cancer diagnosis.

Authors:  Erin L Van Blarigan; Jeffrey A Meyerhardt
Journal:  J Clin Oncol       Date:  2015-04-27       Impact factor: 44.544

Review 8.  Progress and opportunities in molecular pathological epidemiology of colorectal premalignant lesions.

Authors:  Paul Lochhead; Andrew T Chan; Edward Giovannucci; Charles S Fuchs; Kana Wu; Reiko Nishihara; Michael O'Brien; Shuji Ogino
Journal:  Am J Gastroenterol       Date:  2014-06-17       Impact factor: 10.864

9.  TIME (Tumor Immunity in the MicroEnvironment) classification based on tumor CD274 (PD-L1) expression status and tumor-infiltrating lymphocytes in colorectal carcinomas.

Authors:  Tsuyoshi Hamada; Thing Rinda Soong; Yohei Masugi; Keisuke Kosumi; Jonathan A Nowak; Annacarolina da Silva; Xinmeng Jasmine Mu; Tyler S Twombly; Hideo Koh; Juhong Yang; Mingyang Song; Li Liu; Mancang Gu; Yan Shi; Katsuhiko Nosho; Teppei Morikawa; Kentaro Inamura; Sachet A Shukla; Catherine J Wu; Levi A Garraway; Xuehong Zhang; Kana Wu; Jeffrey A Meyerhardt; Andrew T Chan; Jonathan N Glickman; Scott J Rodig; Gordon J Freeman; Charles S Fuchs; Reiko Nishihara; Marios Giannakis; Shuji Ogino
Journal:  Oncoimmunology       Date:  2018-03-19       Impact factor: 8.110

10.  Enhancement of Pathologist's Routine Practice: Reuse of DNA Extracted from Immunostained Formalin-fixed Paraffin-embedded (FFPE) Slides in Downstream Molecular Analysis of Cancer.

Authors:  Asmaa Al-Attas; Mourad Assidi; Jaudah Al-Maghrabi; Ashraf Dallol; Hans-Juergen Schulten; Muhammad Abu-Elmagd; Adeel Chaudhary; Adel Abuzenadah; Bruce Budowle; Abdelbaset Buhmeida; Mohammed Al-Qahtani
Journal:  Cancer Genomics Proteomics       Date:  2016 09-10       Impact factor: 4.069

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.